Abstract
Inflammation plays a key role in atherogenesis.1 High-sensitivity C-reactive protein (hsCRP) and other inflammatory biomarkers can predict atherosclerotic cardiovascular disease (ASCVD) events independently of traditional risk factors.2 The efficacy of statins in mitigating cardiovascular risk may in part be due to their anti-inflammatory properties.3 The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin confirmed the benefit of statins for ASCVD risk-lowering among individuals with elevated hsCRP levels (≥2 mg/L), but with low-density lipoprotein cholesterol (LDL-C) levels of less than 130 mg/dL.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
